These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7544732)

  • 1. Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
    Eri LM; Urdal P
    Eur Urol; 1995; 27(4):274-9. PubMed ID: 7544732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
    Eri LM; Urdal P; Bechensteen AG
    J Urol; 1995 Jul; 154(1):100-4. PubMed ID: 7539852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Br J Urol; 1995 Mar; 75(3):335-40. PubMed ID: 7537602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    Eur Urol; 1994; 26(3):219-26. PubMed ID: 7528662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    J Urol; 1993 Jul; 150(1):90-4. PubMed ID: 7685428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
    Strutt KL; Blackledge GR; Kennealey GT
    J Urol; 1994 May; 151(5):1355-6. PubMed ID: 7512665
    [No Abstract]   [Full Text] [Related]  

  • 7. Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group.
    Tyrrell CJ; Denis L; Newling D; Soloway M; Channer K; Cockshott ID
    Eur Urol; 1998; 33(1):39-53. PubMed ID: 9471040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
    Tyrrell CJ
    Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
    Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Casodex (ICI 176,334), a new, non-steroidal anti-androgen. Early clinical results.
    Lunglmayr G
    Horm Res; 1989; 32 Suppl 1():77-81. PubMed ID: 2515147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extruded dry beans and serum lipoprotein and plasma haemostatic factors in hyperlipidaemic men.
    Oosthuizen W; Scholtz CS; Vorster HH; Jerling JC; Vermaak WJ
    Eur J Clin Nutr; 2000 May; 54(5):373-9. PubMed ID: 10822283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of erection function in patients with prostatic carcinoma treated with Casodex].
    Migliari R; Muscas G; Melis M; Garau M; Sorgia M; Scarpa RM; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):155-61. PubMed ID: 1830408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].
    Salvador C; Planas J; Raventós C; Ropero J; Placer J; López MA; Morote J
    Actas Urol Esp; 2012 Apr; 36(4):205-9. PubMed ID: 22178349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.
    Vigna GB; Donegà P; Zanca R; Barban A; Passaro A; Pansini F; Bonaccorsi G; Mollica G; Fellin R
    Metabolism; 2002 Nov; 51(11):1463-70. PubMed ID: 12404199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
    Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D
    J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men.
    Berg G; Schreier L; Geloso G; Otero P; Nagelberg A; Levalle O
    Horm Metab Res; 2002 Feb; 34(2):87-92. PubMed ID: 11972293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.